Renal Insufficiency Market Report 2026

The renal insufficiency market size has grown rapidly in recent years. It will grow from $12.1 billion in 2025 to $13.48 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rising prevalence of diabetes and hypertension, expansion of dialysis center networks, increased use of ACE inhibitors and ARBs, growing diagnosis of chronic kidney disease, improved access to renal care services.

The renal insufficiency market size is expected to see rapid growth in the next few years. It will grow to $20.51 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing adoption of home dialysis solutions, rising investments in regenerative therapies, expansion of digital patient monitoring, growing demand for personalized renal treatment plans, increasing focus on slowing disease progression. Major trends in the forecast period include increasing adoption of advanced dialysis modalities, rising focus on early disease stage management, growing use of combination drug therapies, expansion of home-based treatment options, enhanced emphasis on patient-centric care models.

The rising incidence of high blood pressure and diabetes is anticipated to drive the growth of the renal insufficiency market in the coming years. High blood pressure and diabetes are largely associated with factors such as unhealthy dietary habits, physical inactivity, obesity, genetic susceptibility, and an aging population. Hypertension damages renal blood vessels by causing scarring and reducing filtration capacity, while diabetes leads to thickening and overexertion of kidney vessels due to prolonged high blood glucose levels. Together, these conditions accelerate kidney damage and contribute significantly to the development of renal insufficiency. For example, in May 2024, according to the National Health Service, a UK-based government agency, the number of high blood pressure diagnoses in the South East of England increased by 71,120 patients in December 2023, representing a 5.4% rise compared to December 2022. Additionally, in April 2023, according to the British Diabetic Association, a UK-based charitable organization, approximately 4.3 million people in the UK were living with a diabetes diagnosis. Therefore, the growing prevalence of high blood pressure and diabetes is fueling the growth of the renal insufficiency market.

Major companies operating in the renal insufficiency market are focusing on the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address both renal and cardiovascular complications in patients with diabetes and chronic kidney disease (CKD). GLP-1 receptor agonists help improve glycemic control, reduce inflammation, and lower oxidative stress in the kidneys, thereby slowing the progression of renal insufficiency. For instance, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Ozempic (semaglutide) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This approval underscores the increasing focus on GLP-1 receptor agonists as a dual therapeutic strategy for managing both diabetes and renal insufficiency, addressing critical unmet needs among patients with progressive CKD.

In February 2023, AstraZeneca PLC, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca expanded its cardiorenal portfolio by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor intended to lower blood pressure in patients with treatment-resistant hypertension. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company developing therapies for individuals with moderate to severe renal impairment or kidney failure.

Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the renal insufficiency market in 2025. The regions covered in the renal insufficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the renal insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the renal insufficiency market by increasing costs of imported dialysis machines, pharmaceutical drugs, medical disposables, and diagnostic equipment. Dialysis centers and hospitals in North America and Europe are most affected due to reliance on imported treatment infrastructure, while Asia-Pacific faces higher costs for exported renal care devices. These tariffs are raising treatment expenses and affecting service expansion. However, they are also supporting domestic manufacturing of dialysis equipment, regional drug production, and localized innovation in renal care technologies.

The renal insufficiency market research report is one of a series of new reports that provides renal insufficiency market statistics, including renal insufficiency industry global market size, regional shares, competitors with a renal insufficiency market share, detailed renal insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the renal insufficiency industry. This renal insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Renal insufficiency refers to a decreased ability of the kidneys to filter waste materials and regulate fluid and electrolyte balance in the body. It may arise from chronic conditions such as diabetes and hypertension or from acute kidney injury, resulting in the buildup of toxins in the bloodstream. If not properly managed, renal insufficiency can progress to chronic kidney disease (CKD) or kidney failure, necessitating dialysis or kidney transplantation.

The main treatment options for renal insufficiency include medications, dialysis, kidney transplantation, and others. Medications used in renal insufficiency help control symptoms, slow disease progression, and manage complications such as hypertension, diabetes, and anemia. The condition is categorized into various disease stages, including different stages of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Distribution channels for treatments include hospital pharmacies, retail pharmacies, and online pharmacies. The key end users include dialysis centers, hospitals and clinics, and research and academic institutes.

The renal insufficiency market consists of sales of dialysis equipment, renal replacement therapies, kidney transplantation services, and pharmaceutical treatments for managing kidney function. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.